Abiraterone
The serum concentration of Atorvastatin can be increased when it is combined with Abiraterone.
Acetaminophen
The risk or severity of adverse effects can be increased when Acetaminophen is combined with Atorvastatin.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Atorvastatin.
Advertisement
Acetohexamide
Atorvastatin may increase the hypoglycemic activities of Acetohexamide.
Acipimox
Acipimox may increase the myopathic rhabdomyolysis activities of Atorvastatin.
Ado-Trastuzumab Emtansine
The risk or severity of rhabdomyolysis can be increased when Trastuzumab emtansine is combined with Atorvastatin.
Advertisement
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Atorvastatin.
Albuterol
The risk or severity of adverse effects can be increased when Salbutamol is combined with Atorvastatin.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atorvastatin.
Advertisement
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Atorvastatin.
Aluminum
The serum concentration of Atorvastatin can be decreased when it is combined with Aluminium.
Aluminum Hydroxide
The serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The serum concentration of Atorvastatin can be decreased when it is combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The serum concentration of Atorvastatin can be decreased when it is combined with Almasilate.
Ambroxol
The risk or severity of adverse effects can be increased when Ambroxol is combined with Atorvastatin.
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Atorvastatin.
Amlodipine
The risk or severity of adverse effects can be increased when Amlodipine is combined with Atorvastatin.
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Atorvastatin.
Amphotericin B
The risk or severity of rhabdomyolysis can be increased when Amphotericin B is combined with Atorvastatin.
amphotericin B liposomal
The risk or severity of rhabdomyolysis can be increased when Amphotericin B is combined with Atorvastatin.
Amprenavir
The risk or severity of adverse effects can be increased when Amprenavir is combined with Atorvastatin.
Anastrozole
The risk or severity of adverse effects can be increased when Anastrozole is combined with Atorvastatin.
Anhydrous Tacrolimus
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Atorvastatin.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Atorvastatin.
Apalutamide
The serum concentration of Atorvastatin can be decreased when it is combined with Apalutamide.
Aprepitant
The risk or severity of adverse effects can be increased when Aprepitant is combined with Atorvastatin.
Aripiprazole
The serum concentration of Aripiprazole can be decreased when it is combined with Atorvastatin.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Atorvastatin.
Astemizole
The risk or severity of adverse effects can be increased when Astemizole is combined with Atorvastatin.
Atazanavir
The risk or severity of adverse effects can be increased when Atazanavir is combined with Atorvastatin.
Atomoxetine
The risk or severity of adverse effects can be increased when Atomoxetine is combined with Atorvastatin.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Atorvastatin.
Azithromycin
The serum concentration of Atorvastatin can be increased when it is combined with Azithromycin.
Benazepril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Benazepril.
Betamethasone
The risk or severity of adverse effects can be increased when Betamethasone is combined with Atorvastatin.
Bexarotene
The serum concentration of Atorvastatin can be decreased when it is combined with Bexarotene.
Bezafibrate
Bezafibrate may increase the myopathic rhabdomyolysis activities of Atorvastatin.
Bicalutamide
The risk or severity of adverse effects can be increased when Bicalutamide is combined with Atorvastatin.
Bifonazole
The risk or severity of adverse effects can be increased when Bifonazole is combined with Atorvastatin.
Bismuth Subcitrate
The serum concentration of Atorvastatin can be decreased when it is combined with Bismuth Subcitrate.
Boceprevir
The serum concentration of Atorvastatin can be increased when it is combined with Boceprevir.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Atorvastatin.
Bosentan
The metabolism of Atorvastatin can be increased when combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Atorvastatin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Atorvastatin.
Brentuximab Vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atorvastatin.
Brigatinib
The serum concentration of Atorvastatin can be decreased when it is combined with Brigatinib.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Atorvastatin.
Buprenorphine
The risk or severity of adverse effects can be increased when Buprenorphine is combined with Atorvastatin.
Butoconazole
The risk or severity of myopathy can be increased when Butoconazole is combined with Atorvastatin.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Atorvastatin.
Caffeine
The risk or severity of adverse effects can be increased when Caffeine is combined with Atorvastatin.
Calcium Carbonate
The serum concentration of Atorvastatin can be decreased when it is combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The serum concentration of Atorvastatin can be decreased when it is combined with Calcium Carbonate.
Capsaicin
The risk or severity of adverse effects can be increased when Capsaicin is combined with Atorvastatin.
Captopril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Captopril.
Carbamazepine
The metabolism of Atorvastatin can be increased when combined with Carbamazepine.
Caspofungin
The risk or severity of adverse effects can be increased when Caspofungin is combined with Atorvastatin.
Celecoxib
The metabolism of Atorvastatin can be decreased when combined with Celecoxib.
Ceritinib
The risk or severity of adverse effects can be increased when Ceritinib is combined with Atorvastatin.
Cerivastatin
The risk or severity of adverse effects can be increased when Cerivastatin is combined with Atorvastatin.
Chloramphenicol
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Atorvastatin.
Chlorpropamide
Atorvastatin may increase the hypoglycemic activities of Chlorpropamide.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Atorvastatin.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cilazapril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Cilazapril.
Cilostazol
The risk or severity of adverse effects can be increased when Cilostazol is combined with Atorvastatin.
Cimetidine
The risk or severity of adverse effects can be increased when Cimetidine is combined with Atorvastatin.
Ciprofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofibrate is combined with Atorvastatin.
Ciprofloxacin
The risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Atorvastatin.
Cisapride
The risk or severity of adverse effects can be increased when Cisapride is combined with Atorvastatin.
Clarithromycin
The serum concentration of Atorvastatin can be increased when it is combined with Clarithromycin.
Clemastine
The risk or severity of adverse effects can be increased when Clemastine is combined with Atorvastatin.
Clindamycin
The risk or severity of adverse effects can be increased when Clindamycin is combined with Atorvastatin.
Clofazimine
The risk or severity of adverse effects can be increased when Clofazimine is combined with Atorvastatin.
Clofezone
The risk or severity of adverse effects can be increased when Rabeprazole is combined with Atorvastatin.
Clomiphene
The risk or severity of adverse effects can be increased when Clomifene is combined with Atorvastatin.
Clotiazepam
The risk or severity of adverse effects can be increased when Clotiazepam is combined with Atorvastatin.
Clotrimazole
The risk or severity of adverse effects can be increased when Clotrimazole is combined with Atorvastatin.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Atorvastatin.
Cobicistat
The serum concentration of Atorvastatin can be increased when it is combined with Cobicistat.
Cocaine
The risk or severity of adverse effects can be increased when Cocaine is combined with Atorvastatin.
Colchicine
The risk or severity of adverse effects can be increased when Colchicine is combined with Atorvastatin.
Colesevelam
Colesevelam can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Atorvastatin.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Atorvastatin.
Crisaborole
The metabolism of Atorvastatin can be decreased when combined with Crisaborole.
Crizotinib
The risk or severity of adverse effects can be increased when Crizotinib is combined with Atorvastatin.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Atorvastatin.
Cyclophosphamide Anhydrous
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Atorvastatin.
Cyclosporine
The serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.
Cyproterone Acetate
The serum concentration of Atorvastatin can be increased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atorvastatin.
Dabrafenib
The serum concentration of Atorvastatin can be decreased when it is combined with Dabrafenib.
Daclatasvir
The serum concentration of Atorvastatin can be increased when it is combined with Daclatasvir.
Dalfopristin
The risk or severity of adverse effects can be increased when Dalfopristin is combined with Atorvastatin.
Danazol
The risk or severity of adverse effects can be increased when Danazol is combined with Atorvastatin.
Daptomycin
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Daptomycin.
Darunavir
The risk or severity of adverse effects can be increased when Darunavir is combined with Atorvastatin.
Dasabuvir
The serum concentration of Atorvastatin can be increased when it is combined with Dasabuvir.
Dasatinib
The risk or severity of adverse effects can be increased when Dasatinib is combined with Atorvastatin.
Dasatinib Anhydrous
The risk or severity of adverse effects can be increased when Dasatinib is combined with Atorvastatin.
Daunorubicin
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Atorvastatin.
Deferasirox
The serum concentration of Atorvastatin can be decreased when it is combined with Deferasirox.
Delavirdine
The risk or severity of adverse effects can be increased when Delavirdine is combined with Atorvastatin.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Atorvastatin.
Dexamethasone
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Atorvastatin.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Atorvastatin.
Diethylstilbestrol
The risk or severity of adverse effects can be increased when Diethylstilbestrol is combined with Atorvastatin.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Atorvastatin.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Atorvastatin.
Diltiazem
The serum concentration of Diltiazem can be increased when it is combined with Atorvastatin.
Dimethyl Sulfoxide
The risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin.
Dirithromycin
The risk or severity of rhabdomyolysis can be increased when Dirithromycin is combined with Atorvastatin.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Atorvastatin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Atorvastatin.
Doxorubicin
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Atorvastatin.
Doxorubicin Hydrochloride
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Atorvastatin.
Doxycycline
The risk or severity of adverse effects can be increased when Doxycycline is combined with Atorvastatin.
Doxycycline Anhydrous
The risk or severity of adverse effects can be increased when Doxycycline is combined with Atorvastatin.
Dronedarone
The risk or severity of adverse effects can be increased when Dronedarone is combined with Atorvastatin.
Econazole
The risk or severity of adverse effects can be increased when Econazole is combined with Atorvastatin.
Econazole Nitrate
The risk or severity of adverse effects can be increased when Econazole is combined with Atorvastatin.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Atorvastatin.
Efavirenz
The risk or severity of adverse effects can be increased when Efavirenz is combined with Atorvastatin.
Efinaconazole
The risk or severity of myopathy can be increased when Efinaconazole is combined with Atorvastatin.
Elbasvir
The risk or severity of adverse effects can be increased when Elbasvir is combined with Atorvastatin.
Eltrombopag
The serum concentration of Atorvastatin can be increased when it is combined with Eltrombopag.
Enalapril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Enalaprilat.
Enasidenib
The risk or severity of adverse effects can be increased when Enasidenib is combined with Atorvastatin.
Enzalutamide
The serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide.
Epinephrine
The risk or severity of adverse effects can be increased when Epinephrine is combined with Atorvastatin.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Atorvastatin.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Atorvastatin.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Atorvastatin.
Erlotinib
The risk or severity of adverse effects can be increased when Erlotinib is combined with Atorvastatin.
Erythromycin
The serum concentration of Atorvastatin can be increased when it is combined with Erythromycin.
Ethanol
The risk or severity of adverse effects can be increased when Ethanol is combined with Atorvastatin.
Etoposide
The risk or severity of adverse effects can be increased when Etoposide is combined with Atorvastatin.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Atorvastatin.
Etravirine
The serum concentration of Atorvastatin can be decreased when it is combined with Etravirine.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Atorvastatin.
Ezetimibe
The risk or severity of adverse effects can be increased when Ezetimibe is combined with Atorvastatin.
Felodipine
The risk or severity of adverse effects can be increased when Felodipine is combined with Atorvastatin.
Fenofibrate
The risk or severity of myopathy and rhabdomyolysis can be increased when Fenofibrate is combined with Atorvastatin.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Atorvastatin.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Atorvastatin.
Fidaxomicin
The risk or severity of adverse effects can be increased when Fidaxomicin is combined with Atorvastatin.
Fluconazole
The serum concentration of Atorvastatin can be increased when it is combined with Fluconazole.
Fluoxetine
The risk or severity of adverse effects can be increased when Fluoxetine is combined with Atorvastatin.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Atorvastatin.
Fluvastatin
The risk or severity of adverse effects can be increased when Fluvastatin is combined with Atorvastatin.
Fluvoxamine
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Atorvastatin.
Fosamprenavir
The risk or severity of adverse effects can be increased when Fosamprenavir is combined with Atorvastatin.
Fosaprepitant
The risk or severity of adverse effects can be increased when Fosaprepitant is combined with Atorvastatin.
Fosinopril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Fosinopril.
Fosphenytoin
The serum concentration of Atorvastatin can be decreased when it is combined with Fosphenytoin.
Fusidate
The serum concentration of Atorvastatin can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Atorvastatin can be increased when it is combined with Fusidic Acid.
Gemfibrozil
The risk or severity of adverse effects can be increased when Gemfibrozil is combined with Atorvastatin.
Glibornuride
Atorvastatin may increase the hypoglycemic activities of Glibornuride.
Gliclazide
Atorvastatin may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Atorvastatin may increase the hypoglycemic activities of Glimepiride.
Glipizide
Atorvastatin may increase the hypoglycemic activities of Glipizide.
Gliquidone
Atorvastatin may increase the hypoglycemic activities of Gliquidone.
Glyburide
The risk or severity of adverse effects can be increased when Glyburide is combined with Atorvastatin.
Glycerol Phenylbutyrate
The risk or severity of adverse effects can be increased when Glycerol Phenylbutyrate is combined with Atorvastatin.
Haloperidol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Atorvastatin.
Histamine
The risk or severity of adverse effects can be increased when Histamine is combined with Atorvastatin.
Hydralazine
The risk or severity of adverse effects can be increased when Hydralazine is combined with Atorvastatin.
Hydrocortisone
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Atorvastatin.
Hydrotalcite
The serum concentration of Atorvastatin can be decreased when it is combined with Hydrotalcite.
Hypoxis hemerocallidea root extract
The metabolism of Atorvastatin can be increased when combined with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Atorvastatin.
Idelalisib
The risk or severity of adverse effects can be increased when Idelalisib is combined with Atorvastatin.
Ifosfamide
The risk or severity of adverse effects can be increased when Ifosfamide is combined with Atorvastatin.
Iloperidone
The risk or severity of adverse effects can be increased when Iloperidone is combined with Atorvastatin.
Imatinib
The risk or severity of adverse effects can be increased when Imatinib is combined with Atorvastatin.
Imidapril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Imidapril.
Indinavir
The risk or severity of adverse effects can be increased when Indinavir is combined with Atorvastatin.
INDINAVIR ANHYDROUS
The risk or severity of adverse effects can be increased when Indinavir is combined with Atorvastatin.
insulin human, rDNA origin
Atorvastatin may increase the hypoglycemic activities of Insulin Human.
Insulin, Pork
Atorvastatin may increase the hypoglycemic activities of Insulin Pork.
Insulin, Regular, Pork
Atorvastatin may increase the hypoglycemic activities of Insulin Pork.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Atorvastatin.
Irinotecan
The risk or severity of adverse effects can be increased when Irinotecan is combined with Atorvastatin.
Isavuconazole
The serum concentration of Atorvastatin can be increased when it is combined with Isavuconazole.
Isavuconazonium
The risk or severity of adverse effects can be increased when Isavuconazonium is combined with Atorvastatin.
Isoconazole
The risk or severity of myopathy can be increased when Isoconazole is combined with Atorvastatin.
Isoniazid
The risk or severity of adverse effects can be increased when Isoniazid is combined with Atorvastatin.
Isradipine
The risk or severity of adverse effects can be increased when Isradipine is combined with Atorvastatin.
Itraconazole
The risk or severity of adverse effects can be increased when Itraconazole is combined with Atorvastatin.
Ivacaftor
The risk or severity of adverse effects can be increased when Ivacaftor is combined with Atorvastatin.
Ivermectin
The risk or severity of rhabdomyolysis can be increased when Ivermectin is combined with Atorvastatin.
Ixabepilone
The risk or severity of rhabdomyolysis can be increased when Ixabepilone is combined with Atorvastatin.
Josamycin
The risk or severity of adverse effects can be increased when Josamycin is combined with Atorvastatin.
Ketazolam
The risk or severity of adverse effects can be increased when Ketazolam is combined with Atorvastatin.
Ketoconazole
The serum concentration of Atorvastatin can be increased when it is combined with Ketoconazole.
Lansoprazole
The risk or severity of adverse effects can be increased when Lansoprazole is combined with Atorvastatin.
Lanthanum Carbonate
The serum concentration of Atorvastatin can be decreased when it is combined with Lanthanum carbonate.
Lapatinib
The risk or severity of adverse effects can be increased when Lapatinib is combined with Atorvastatin.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Atorvastatin.
Lercanidipine
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Atorvastatin.
Levalbuterol
The risk or severity of adverse effects can be increased when Levosalbutamol is combined with Atorvastatin.
Levofloxacin
The risk or severity of adverse effects can be increased when Levofloxacin is combined with Atorvastatin.
Levofloxacin Anhydrous
The risk or severity of adverse effects can be increased when Levofloxacin is combined with Atorvastatin.
Lidocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Atorvastatin.
Linagliptin
The risk or severity of adverse effects can be increased when Linagliptin is combined with Atorvastatin.
Lisinopril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Atorvastatin.
Lomitapide
The risk or severity of adverse effects can be increased when Lomitapide is combined with Atorvastatin.
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Atorvastatin.
Lopinavir
The risk or severity of adverse effects can be increased when Lopinavir is combined with Atorvastatin.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Atorvastatin.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Atorvastatin.
Lovastatin
The risk or severity of adverse effects can be increased when Lovastatin is combined with Atorvastatin.
Luliconazole
The risk or severity of adverse effects can be increased when Luliconazole is combined with Atorvastatin.
Lumacaftor
The serum concentration of Atorvastatin can be increased when it is combined with Lumacaftor.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Atorvastatin.
Magaldrate
The serum concentration of Atorvastatin can be decreased when it is combined with Magaldrate.
Magnesium Hydroxide
The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium hydroxide.
Magnesium Oxide
The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.
Magnesium Trisilicate
The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium Trisilicate.
Manidipine
The risk or severity of adverse effects can be increased when Manidipine is combined with Atorvastatin.
Mefloquine
The risk or severity of adverse effects can be increased when Mefloquine is combined with Atorvastatin.
Mequitazine
The risk or severity of adverse effects can be increased when Mequitazine is combined with Atorvastatin.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Atorvastatin.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Atorvastatin.
Methazolamide
The risk or severity of adverse effects can be increased when Methazolamide is combined with Atorvastatin.
Methimazole
The risk or severity of adverse effects can be increased when Methimazole is combined with Atorvastatin.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Atorvastatin.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Atorvastatin.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Atorvastatin.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Atorvastatin.
Metronidazole
The risk or severity of adverse effects can be increased when Metronidazole is combined with Atorvastatin.
Metyrapone
The risk or severity of adverse effects can be increased when Metyrapone is combined with Atorvastatin.
Mibefradil
The risk or severity of adverse effects can be increased when Mibefradil is combined with Atorvastatin.
Miconazole
The risk or severity of adverse effects can be increased when Miconazole is combined with Atorvastatin.
Midazolam
The serum concentration of Midazolam can be increased when it is combined with Atorvastatin.
Mifepristone
The risk or severity of adverse effects can be increased when Mifepristone is combined with Atorvastatin.
Mirtazapine
The risk or severity of adverse effects can be increased when Mirtazapine is combined with Atorvastatin.
Mitotane
The serum concentration of Atorvastatin can be decreased when it is combined with Mitotane.
Mitoxantrone
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Atorvastatin.
Modafinil
The risk or severity of adverse effects can be increased when Modafinil is combined with Atorvastatin.
Moexipril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Moexipril.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Atorvastatin.
Natamycin
The risk or severity of rhabdomyolysis can be increased when Natamycin is combined with Atorvastatin.
Nefazodone
The risk or severity of adverse effects can be increased when Nefazodone is combined with Atorvastatin.
Nelfinavir
The risk or severity of adverse effects can be increased when Nelfinavir is combined with Atorvastatin.
Netupitant
The risk or severity of adverse effects can be increased when Netupitant is combined with Atorvastatin.
Nevirapine
The risk or severity of adverse effects can be increased when Nevirapine is combined with Atorvastatin.
Niacin
The risk or severity of rhabdomyolysis can be increased when Niacin is combined with Atorvastatin.
Niacinamide
The risk or severity of adverse effects can be increased when Nicotinamide is combined with Atorvastatin.
Nicardipine
The risk or severity of adverse effects can be increased when Nicardipine is combined with Atorvastatin.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Atorvastatin.
Nifedipine
The risk or severity of adverse effects can be increased when Nifedipine is combined with Atorvastatin.
Nilotinib
The risk or severity of adverse effects can be increased when Nilotinib is combined with Atorvastatin.
Nilvadipine
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Atorvastatin.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Atorvastatin.
Nisoldipine
The risk or severity of adverse effects can be increased when Nisoldipine is combined with Atorvastatin.
Nitrendipine
The risk or severity of adverse effects can be increased when Nitrendipine is combined with Atorvastatin.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Atorvastatin.
Norfloxacin
The risk or severity of adverse effects can be increased when Norfloxacin is combined with Atorvastatin.
Noscapine
The risk or severity of adverse effects can be increased when Noscapine is combined with Atorvastatin.
Nystatin
The risk or severity of rhabdomyolysis can be increased when Nystatin is combined with Atorvastatin.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Atorvastatin.
Olaparib
The risk or severity of adverse effects can be increased when Olaparib is combined with Atorvastatin.
Ombitasvir
The serum concentration of Atorvastatin can be increased when it is combined with Ombitasvir.
Omeprazole
The risk or severity of adverse effects can be increased when Omeprazole is combined with Atorvastatin.
Osimertinib
The serum concentration of Atorvastatin can be increased when it is combined with Osimertinib.
Oxiconazole
The risk or severity of myopathy can be increased when Oxiconazole is combined with Atorvastatin.
Oxybutynin
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Atorvastatin.
Oxymetholone
The risk or severity of adverse effects can be increased when Oxymetholone is combined with Atorvastatin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Atorvastatin.
Palbociclib
The risk or severity of adverse effects can be increased when Palbociclib is combined with Atorvastatin.
Paramethasone
The risk or severity of adverse effects can be increased when Paramethasone is combined with Atorvastatin.
Paritaprevir
The serum concentration of Atorvastatin can be increased when it is combined with Paritaprevir.
Pazopanib
The risk or severity of adverse effects can be increased when Pazopanib is combined with Atorvastatin.
Pentobarbital
The metabolism of Atorvastatin can be increased when combined with Pentobarbital.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Atorvastatin.
Perindopril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Perindopril.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Atorvastatin.
Phenobarbital
The metabolism of Atorvastatin can be increased when combined with Phenobarbital.
Phenytoin
The serum concentration of Atorvastatin can be decreased when it is combined with Phenytoin.
Pilocarpine
The risk or severity of adverse effects can be increased when Pilocarpine is combined with Atorvastatin.
Pimecrolimus
The risk or severity of rhabdomyolysis can be increased when Pimecrolimus is combined with Atorvastatin.
Pimozide
The risk or severity of adverse effects can be increased when Pimozide is combined with Atorvastatin.
Pioglitazone
The metabolism of Atorvastatin can be decreased when combined with Pioglitazone.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Atorvastatin.
Posaconazole
The serum concentration of Atorvastatin can be increased when it is combined with Posaconazole.
Pravastatin
The risk or severity of adverse effects can be increased when Pravastatin is combined with Atorvastatin.
Prednisolone
The risk or severity of adverse effects can be increased when Prednisolone is combined with Atorvastatin.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Atorvastatin.
Primaquine
The risk or severity of adverse effects can be increased when Primaquine is combined with Atorvastatin.
Primidone
The metabolism of Atorvastatin can be increased when combined with Primidone.
Progesterone
The risk or severity of adverse effects can be increased when Progesterone is combined with Atorvastatin.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Atorvastatin.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Atorvastatin.
Quinapril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Quinapril.
Quinidine
The risk or severity of adverse effects can be increased when Quinidine is combined with Atorvastatin.
Quinine
The risk or severity of renal failure and rhabdomyolysis can be increased when Quinine is combined with Atorvastatin.
Quinupristin
The risk or severity of adverse effects can be increased when Quinupristin is combined with Atorvastatin.
Rabeprazole
The risk or severity of adverse effects can be increased when Rabeprazole is combined with Atorvastatin.
Raloxifene
The risk or severity of adverse effects can be increased when Raloxifene is combined with Atorvastatin.
Raltegravir
Raltegravir may increase the myopathic rhabdomyolysis activities of Atorvastatin.
Ramipril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Ramipril.
Ranitidine
The risk or severity of adverse effects can be increased when Ranitidine is combined with Atorvastatin.
Ranolazine
The serum concentration of Atorvastatin can be increased when it is combined with Ranolazine.
Regorafenib
The risk or severity of adverse effects can be increased when Regorafenib is combined with Atorvastatin.
Regular Insulin, Human
Atorvastatin may increase the hypoglycemic activities of Insulin Human.
Repaglinide
The risk or severity of adverse effects can be increased when Repaglinide is combined with Atorvastatin.
Rescinnamine
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Atorvastatin.
Ribociclib
The serum concentration of Atorvastatin can be increased when it is combined with Ribociclib.
Rifabutin
The metabolism of Atorvastatin can be increased when combined with Rifabutin.
Rifampin
The metabolism of Atorvastatin can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Atorvastatin can be increased when combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Atorvastatin.
Rilpivirine
The serum concentration of Atorvastatin can be increased when it is combined with Rilpivirine.
Risperidone
The risk or severity of adverse effects can be increased when Risperidone is combined with Atorvastatin.
Ritonavir
The serum concentration of Atorvastatin can be increased when it is combined with Ritonavir.
Rivastigmine
The risk or severity of adverse effects can be increased when Rivastigmine is combined with Atorvastatin.
Rolitetracycline
The risk or severity of adverse effects can be increased when Rolitetracycline is combined with Atorvastatin.
Rosiglitazone
The metabolism of Atorvastatin can be decreased when combined with Rosiglitazone.
Rosuvastatin
The risk or severity of adverse effects can be increased when Rosuvastatin is combined with Atorvastatin.
Roxithromycin
The risk or severity of adverse effects can be increased when Roxithromycin is combined with Atorvastatin.
Rucaparib
The risk or severity of adverse effects can be increased when Rucaparib is combined with Atorvastatin.
Rutin
The risk or severity of adverse effects can be increased when Rutin is combined with Atorvastatin.
Saquinavir
The risk or severity of adverse effects can be increased when Saquinavir is combined with Atorvastatin.
Saquinavir Mesylate
The risk or severity of adverse effects can be increased when Saquinavir is combined with Atorvastatin.
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Atorvastatin.
Saxagliptin
The serum concentration of Saxagliptin can be decreased when it is combined with Atorvastatin.
Saxagliptin Anhydrous
The serum concentration of Saxagliptin can be decreased when it is combined with Atorvastatin.
Secobarbital
The metabolism of Atorvastatin can be increased when combined with Secobarbital.
Sertaconazole
The risk or severity of myopathy can be increased when Sertaconazole is combined with Atorvastatin.
Sertraline
The risk or severity of adverse effects can be increased when Sertraline is combined with Atorvastatin.
Sildenafil
The risk or severity of adverse effects can be increased when Sildenafil is combined with Atorvastatin.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Atorvastatin.
Siltuximab
The serum concentration of Atorvastatin can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Atorvastatin can be increased when it is combined with Simeprevir.
Simvastatin
The risk or severity of adverse effects can be increased when Simvastatin is combined with Atorvastatin.
Sirolimus
The risk or severity of adverse effects can be increased when Sirolimus is combined with Atorvastatin.
Sodium Bicarbonate
The serum concentration of Atorvastatin can be decreased when it is combined with Sodium bicarbonate.
Sorafenib
The risk or severity of adverse effects can be increased when Sorafenib is combined with Atorvastatin.
Spiramycin
The risk or severity of adverse effects can be increased when Spiramycin is combined with Atorvastatin.
Spirapril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Spirapril.
ST. JOHN'S WORT EXTRACT
The metabolism of Atorvastatin can be increased when combined with St. John's Wort.
Sulconazole
The risk or severity of myopathy can be increased when Sulconazole is combined with Atorvastatin.
Sulfamethoxazole
The risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Atorvastatin.
Sulfanilamide
The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin.
Sulfinpyrazone
The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Atorvastatin.
Sulfisoxazole
The risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Atorvastatin.
Tacrolimus
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Atorvastatin.
Tadalafil
The risk or severity of adverse effects can be increased when Tadalafil is combined with Atorvastatin.
Tamoxifen
The risk or severity of adverse effects can be increased when Tamoxifen is combined with Atorvastatin.
Telaprevir
The serum concentration of Atorvastatin can be increased when it is combined with Telaprevir.
Telithromycin
The risk or severity of adverse effects can be increased when Telithromycin is combined with Atorvastatin.
Temsirolimus
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Atorvastatin.
Teniposide
The risk or severity of adverse effects can be increased when Teniposide is combined with Atorvastatin.
Terconazole
The risk or severity of myopathy can be increased when Terconazole is combined with Atorvastatin.
Terfenadine
The risk or severity of adverse effects can be increased when Terfenadine is combined with Atorvastatin.
Teriflunomide
The serum concentration of Atorvastatin can be increased when it is combined with Teriflunomide.
Testosterone
The risk or severity of adverse effects can be increased when Testosterone is combined with Atorvastatin.
Testosterone Cypionate
The risk or severity of adverse effects can be increased when Testosterone cypionate is combined with Atorvastatin.
Testosterone Enanthate
The risk or severity of adverse effects can be increased when Testosterone enanthate is combined with Atorvastatin.
Testosterone Undecanoate
The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Atorvastatin.
Tetracycline
The risk or severity of adverse effects can be increased when Tetracycline is combined with Atorvastatin.
Thiopental
The risk or severity of adverse effects can be increased when Thiopental is combined with Atorvastatin.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Thiopental is combined with Atorvastatin.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Atorvastatin.
Ticagrelor
The serum concentration of Atorvastatin can be increased when it is combined with Ticagrelor.
Ticlopidine
The risk or severity of adverse effects can be increased when Ticlopidine is combined with Atorvastatin.
Tilmicosin
The risk or severity of rhabdomyolysis can be increased when Tilmicosin is combined with Atorvastatin.
Tioconazole
The risk or severity of adverse effects can be increased when Tioconazole is combined with Atorvastatin.
Tipranavir
The serum concentration of Atorvastatin can be increased when it is combined with Tipranavir.
Tocilizumab
The serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.
Tofisopam
The risk or severity of adverse effects can be increased when Tofisopam is combined with Atorvastatin.
Tolazamide
Atorvastatin may increase the hypoglycemic activities of Tolazamide.
Tolbutamide
Atorvastatin may increase the hypoglycemic activities of Tolbutamide.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Atorvastatin.
Topotecan
The risk or severity of adverse effects can be increased when Topotecan is combined with Atorvastatin.
Trabectedin
Atorvastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Atorvastatin.
Trandolapril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Trandolapril.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Atorvastatin.
Trimethoprim
The metabolism of Atorvastatin can be decreased when combined with Trimethoprim.
Troglitazone
The risk or severity of adverse effects can be increased when Troglitazone is combined with Atorvastatin.
Troleandomycin
The risk or severity of adverse effects can be increased when Troleandomycin is combined with Atorvastatin.
Tromethamine
The serum concentration of Atorvastatin can be decreased when it is combined with Tromethamine.
Valproate
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Atorvastatin.
Valproic Acid
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Atorvastatin.
Vemurafenib
The serum concentration of Atorvastatin can be decreased when it is combined with Vemurafenib.
Venlafaxine
The risk or severity of adverse effects can be increased when Venlafaxine is combined with Atorvastatin.
Verapamil
Atorvastatin can cause a decrease in the absorption of Verapamil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Vinblastine
The risk or severity of adverse effects can be increased when Vinblastine is combined with Atorvastatin.
Vincristine
The excretion of Vincristine can be decreased when combined with Atorvastatin.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Atorvastatin.
Voriconazole
The risk or severity of adverse effects can be increased when Voriconazole is combined with Atorvastatin.
Zafirlukast
The risk or severity of adverse effects can be increased when Zafirlukast is combined with Atorvastatin.
Ziprasidone
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Atorvastatin.
Zofenopril
The risk or severity of adverse effects can be increased when Atorvastatin is combined with Zofenopril.
